Cytoprotective effects of melatonin on zoledronic acid-treated human osteoblasts

Publication date: Available online 18 April 2017
Source:Journal of Cranio-Maxillofacial Surgery
Author(s): F. Camacho-Alonso, I. Urrutia-Rodríguez, D. Oñate-Cabrerizo, R.E. Oñate-Sánchez, F.J. Rodríguez-Lozano
ObjectiveTo evaluate the cytoprotective effects of melatonin (MLT) on zoledronic acid (ZA)-treated human osteoblasts.MethodsHuman osteoblasts were exposed to ZA (1, 5, 10, 50, 100 and 300 μM) and MLT (1, 10, 50, 100 y 200 μM) for 24, 48 and 72 hours of incubation, to evaluate their effects on cell viability.ResultsAs ZA concentration increased, greater reductions in cell viability of human osteoblasts were induced whether at 24, 48 or 72 hours incubation. At 24 hours incubation with MLT, greatest cell viability was obtained when low dose of MLT was applied (without significant differences); 48 and 72 hours incubation presented the greatest cell viability with the highest MLT concentrations (100 and 200 μM). MLT at concentrations of 100 and 200 μM would appear to have a certain cytoprotective effect on ZA-treated human osteoblasts with low concentrations of ZA (1 y 5 μM), whether at 24, 48 or 72 hours; however, at ZA concentrations ≥10 μM the possible cytoprotective effects of MLT were low at 24 hours incubation.ConclusionsMLT has a cytoprotective effect on ZA-treated human osteoblasts and could represent a promising preventative alternative for patients at risk of bisphosphonate-related osteonecrosis of the jaw.



http://ift.tt/2oVjZ74